Vermont's Attorney General has sued the Sackler family, owners of Purdue Pharma, for allegedly directing a deceptive opioid marketing campain; drug manufacturer Eli Lilly has offered a half-priced, generic version of Humalog insulin; asthma rates for children fell in Los Angeles after air quality improved.
Vermont’s Attorney General T.J. Donovan has sued 8 members of the Sackler family, owners of the company that manufactures OxyContin, CNN reported. Donovan has accused the family members of directing a marketing campaign that minimized the health risks of opioids and encouraged sales representatives to promote higher-dose products, which were more addictive and dangerous. The Sacklers and their company, Purdue Pharma, have denied the allegations and plans to mount a defense.Fulfilling a promise made in March to offer more affordable insulin for patients with diabetes, drug manufacturer Eli Lilly is now selling a half-priced, generic version of Humalog called insulin lispro, Associated Press reported. Lilly said patients who have high-deductible health insurance, are uninsured, or have Medicare Part D plans will experience the greatest cost-savings. The average price of insulin almost tripled from 2002 to 2013 and has risen about 10% per year since then. The generic version will cost about $137.50 per vial or $265.20 for a package of 5 pens, an easier-to-inject option.Improvements in Los Angeles’ air quality have resulted in fewer children being diagnosed with asthma, according to NPR. Researchers at the University of Southern California conducted a study to examine whether stricter regulation of vehicle emissions that improved air quality could lead to better health outcomes. The findings were published yesterday in JAMA, and while they didn’t establish a cause and effect relationship, they provided convincing circumstantial evidence that improvements in air quality could result in fewer illnesses.
Exploring the Potential of Machine Learning in Optimizing Respiratory Failure Treatment
August 9th 2025Machine learning holds promise for optimizing treatment strategies and potentially improving outcomes in respiratory failure but future research and development are necessary to fully realize its potential in clinical practice.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Chronic Respiratory Diseases Linked to Other Noncommunicable Diseases in Vulnerable Countries
August 4th 2025Despite their devastating global impact, chronic respiratory diseases remain a hidden threat in low- and middle-income countries, often going undiagnosed in adults who are already battling other noncommunicable diseases.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
RSV's Impact on Heart Health Emphasizes Broader Risks, Vaccination Importance for Older Adults
July 23rd 2025Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in older adults, underscoring the need for vaccination in this population regardless of their preexisting health conditions.
Read More